Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Robyn Emanuel
Ruxolitinib as an Emerging Treatment in Myelofibrosis
Blood and Lymphatic Cancer: Targets and Therapy
Related publications
Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis
Blood Cancer Journal
Oncology
Hematology
Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Efficacy of Ruxolitinib for Myelofibrosis
Expert Opinion on Pharmacotherapy
Medicine
Pharmacology
Cost-Effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain
Journal of Health Economics and Outcomes Research
Safety and Efficacy of Ruxolitinib in Myelofibrosis Patients Without Splenomegaly
British Journal of Haematology
Hematology
Critical Appraisal of the Role of Ruxolitinib in Myeloproliferative Neoplasm-Associated Myelofibrosis
OncoTargets and Therapy
Oncology
Pharmacology
Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I
Clinical Lymphoma, Myeloma and Leukemia
Cancer Research
Oncology
Hematology
Emerging Drugs for Myelofibrosis
Expert Opinion on Emerging Drugs
Pharmacology
JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis
New England Journal of Medicine
Medicine